Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent Inc (NYSE: CTLT) delivers essential pharmaceutical development solutions and manufacturing services for global healthcare partners. This dedicated news hub provides investors and industry professionals with timely updates on Catalent's operational milestones, strategic initiatives, and regulatory developments.
Access authoritative reporting on material events including clinical manufacturing advancements, drug delivery innovations, and global supply chain expansions. Our curated collection features earnings disclosures, partnership announcements, and facility updates directly impacting Catalent's market position.
Key focus areas include bioavailability enhancement technologies, commercial packaging solutions, and biologics manufacturing capabilities. Monitor critical updates through verified press releases and objective analysis of Catalent's role in accelerating therapeutic development timelines.
Bookmark this page for streamlined tracking of CTLT's progress in formulation science, regulatory submissions, and capacity investments across its global manufacturing network.
Catalent, Inc. (NYSE: CTLT), a global leader in advanced delivery technologies and manufacturing solutions, will present at the BofA Securities 2021 Health Care Conference on May 12, 2021, at 11:45 a.m. ET. The presentation will be available via live webcast on their investor site, with a replay option afterward. Catalent has over 85 years of industry experience, employs more than 14,000 staff, including 2,400 scientists, and generated over $3 billion in revenue in fiscal 2020. The company is headquartered in Somerset, New Jersey.
Catalent, Inc. (NYSE: CTLT) reported a robust third quarter for fiscal 2021, with net revenue of $1.05 billion, up 38% year-over-year. Net earnings were $231.8 million, including a $184 million gain from a business sale. Adjusted EBITDA grew 48% to $274.2 million, and the Biologics segment experienced a remarkable 117% revenue increase. The company has raised its fiscal 2021 guidance, expecting revenues between $3.875 billion to $3.975 billion.
Catalent, Inc. (NYSE: CTLT) will announce its financial results for Q3 of fiscal year 2021, ending March 31, 2021, before the market opens on May 4, 2021. The management will host a webcast at 8:15 a.m. ET to discuss the results. Investors can access the event via Catalent's website, where a supplemental slide presentation will also be available prior to the webcast. Catalent has over 85 years of experience, employs approximately 15,000 staff, and reported over $3 billion in revenue for fiscal 2020.
Moderna and Catalent have expanded their strategic collaboration to include a new high-speed vial filling line at Catalent's Bloomington, Indiana facility dedicated to manufacturing the Moderna COVID-19 Vaccine and other investigational programs. This partnership, initiated in 2016, has previously supported the production of 100 million vaccine doses. The new filling line aims to enhance capacity for ongoing clinical trials and pandemic response efforts. Catalent's acceleration of the project allows for significant production efficiency, freeing up existing lines for other client programs.
Moderna and Catalent have expanded their strategic collaboration, dedicating a new high-speed vial filling line at Catalent's Bloomington facility for the production of the Moderna COVID-19 Vaccine. This expansion follows a successful milestone of 100 million doses achieved in March 2021. The new line will support not only the COVID-19 vaccine but also other investigational programs in Moderna's pipeline until June 2023. Catalent's investment of $50 million will enhance manufacturing capabilities and expedite project timelines.
Cybin, a biotechnology company focused on psychedelic therapeutics, has announced a new partnership with Catalent, the leader in drug delivery technologies. The agreement allows Cybin to utilize Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for its novel drug CYB003, aimed at treating resistant psychiatric disorders. This innovative delivery method promises improved pharmacokinetics by enabling pre-gastric absorption. The project begins in April 2021 with feasibility studies on various ODT formulations.
Catalent, Inc. (NYSE: CTLT), a global leader in drug delivery and manufacturing, announced its executive leadership will present virtually at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 11:20 a.m. ET. A live webcast of the presentation will be available at investor.catalent.com and can be replayed afterward.
Catalent has over 85 years of experience, employs over 14,000 staff, and generated over $3 billion in revenue in fiscal year 2020.
Catalent, Inc. (NYSE: CTLT) announced a private offering of $550 million in 3.125% senior unsecured notes due 2029, increasing from the previously announced size by $75 million. The proceeds will be utilized to redeem existing 4.875% senior notes due 2026, cover related expenses, and enhance cash reserves for general corporate purposes. The offering is exempt from registration requirements and is expected to close on February 22, 2021. The notes will not be guaranteed by Catalent or its parent companies.
Catalent (NYSE: CTLT) announced its subsidiary, Catalent Pharma Solutions, plans to offer $475 million in senior unsecured notes due 2029 in a private offering. The proceeds will be used to redeem its 4.875% senior notes due 2026, cover related fees, and support general corporate purposes, including capital expenditures. The offering is aimed at qualified institutional buyers and is exempt from registration under Securities Act regulations. Notably, there is no guarantee that the offering will be completed or that the redemption of the 2026 notes will occur.
Catalent, Inc. (NYSE: CTLT) announced its financial results for Q2 FY2021, reporting net revenue of $910.8 million, a 26% increase from the previous year. Net earnings were $88.4 million, with earnings per share rising to $0.46. The Biologics segment saw impressive growth, with revenue up 79% year-over-year. Catalent raised its fiscal 2021 guidance, projecting net revenue between $3.80 billion and $3.95 billion. Adjusted EBITDA is expected to range from $950 million to $1,000 million.
